Framatome & IBA – Press Release
Paris, France and Louvain-La-Neuve, Belgium – February 7, 2025
Framatome, an international leader in nuclear energy committed to developing products and services for the healthcare industry, and IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today announced they have signed a Memorandum Of Understanding to start a strategic partnership aimed at advancing industrial-scale production of Astatine-211 (211At), an alpha-emitting radioisotope across Europe and the United States.
211At is a highly promising radioisotope currently being investigated for its potential in targeted alpha-therapies in oncology. The collaboration between Framatome and IBA aims to build a reliable and sustainable network of cutting-edge specialized alpha-emitting cyclotrons, ensuring the timely and consistent production of this alpha-emitting radioisotope, whilst further establishing radio-theranostics as a cornerstone of precision oncology.
The first milestone in this collaboration will be the establishment of a dedicated production pilot facility, set to be installed by 2027-2028. Framatome will make a financial investment in the partnership, with IBA contributing equipment. The facility will be located in the Pays de la Loire region in France, leveraging the region’s strong nuclear medicine research ecosystem and industrial expertise.
Key Quotes
François Gauché, Vice President of Framatome Healthcare: « This partnership with IBA is a significant step toward transforming cancer care through targeted alpha therapy. The secure, scalable, and timely supply of Astatine-211 is vital for addressing unmet medical needs, and we are committed to building a robust production network to serve the growing demand. »
Charles Kumps, President of IBA RadioPharma Solutions: « Today’s announcement is the start of what we believe will be a strong partnership with a shared goal: building a global, reliable industrial network for the timely production and commercialization of Astatine-211 compounds. »
Référence
Source : Framatome & IBA Joint Press Release
Date : 7 février 2025
Lien vers l’article original : Télécharger le communiqué de presse (PDF)